Christin Schild

Bern, BE 3007, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Correction: One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Correction: One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Journal: Ophthalmology and therapy

Published: February 28, 2026

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Journal: Ophthalmology and therapy

Published: January 06, 2026

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Journal: Ophthalmology and therapy

Published: December 01, 2025

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report.

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report.

Journal: Ophthalmology science

Published: November 08, 2025

First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network report.

First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network report.

Journal: BMJ open ophthalmology

Published: September 01, 2025

One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Journal: Ophthalmology and therapy

Published: August 11, 2025

Treatment Cessation in Patients with Diabetic Maculopathy under Intravitreal Anti-VEGF Therapy Following a Treat-and-Extend Protocol.

Treatment Cessation in Patients with Diabetic Maculopathy under Intravitreal Anti-VEGF Therapy Following a Treat-and-Extend Protocol.

Journal: Ophthalmology science

Published: March 31, 2025

One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Journal: Ophthalmology. Retina

Published: December 01, 2024

Predicting long-term functional anti-VEGF treatment outcomes in neovascular AMD in a real-world setting.

Predicting long-term functional anti-VEGF treatment outcomes in neovascular AMD in a real-world setting.

Journal: PloS one

Published: June 11, 2024

Response to the Letter to the Editor by Michael Colucciello, MD, FASRS, Entitled "Steroid/Anti-VEGF Combination Therapy for Neovascular AMD".

Response to the Letter to the Editor by Michael Colucciello, MD, FASRS, Entitled "Steroid/Anti-VEGF Combination Therapy for Neovascular AMD".

Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics

Published: April 03, 2024

Intravitreal Dexamethasone as a Rescue for Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration with Persistent Disease Activity and High Treatment Demand.

Intravitreal Dexamethasone as a Rescue for Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration with Persistent Disease Activity and High Treatment Demand.

Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics

Published: December 20, 2023

Association of inflammation-related markers and diabetic retinopathy severity in the aqueous humor, but not serum of type 2 diabetic patients.

Association of inflammation-related markers and diabetic retinopathy severity in the aqueous humor, but not serum of type 2 diabetic patients.

Journal: PloS one

Published: May 24, 2023

Showing 1-12 of 18

Last Updated: 09/26/2026